PRMT3 and neoplasm: Here, the authors show that targeting PRMT3 markedly improves the anticancer efficacy of ICB via interrupting HSP60 methylation and oligomerization, damaging mitochondrial integrity, and thereby activating cGAS/STING-mediated anti-tumor immunity.